Introduction: Who Should Undergo Diagnostics

Anyone who has been diagnosed with chronic kidney disease should discuss anemia screening with their healthcare provider. This is especially important because anemia typically does not appear in the earliest stages of kidney disease but becomes increasingly common as kidney function declines. When your kidneys are damaged and unable to filter blood properly, they often lose their ability to produce a hormone called erythropoietin, which signals your bone marrow to make red blood cells. Without enough of this hormone, your body cannot produce sufficient red blood cells to carry oxygen throughout your body, resulting in anemia.^[1]

Diagnostic testing becomes particularly important when kidney function drops significantly. Anemia often develops when creatinine clearance—a measure of how well your kidneys filter waste—falls below 45 mL per minute. However, the severity of anemia does not always match the degree of kidney damage, meaning that two people with similar kidney function might experience very different levels of anemia. Certain types of kidney damage, particularly those affecting the glomeruli (the filtering units of the kidney), such as damage from diabetes or amyloidosis, tend to cause more severe anemia relative to the level of kidney function loss.^[5]

If you experience symptoms such as extreme tiredness that does not improve with rest, weakness in your muscles, dizziness, shortness of breath even with minimal activity, unusual coldness when others are comfortable, confusion or difficulty thinking clearly, very pale skin, or ice cravings, you should seek diagnostic evaluation. These symptoms can significantly affect your daily life, making it difficult to perform routine tasks or maintain your usual activities. Some people also experience problems with sleep, mood changes, and sexual function, which can worsen with untreated anemia.^[4]

People with chronic kidney disease should undergo regular diagnostic testing for anemia even if they feel well, as the condition can develop gradually and symptoms may not be immediately obvious. Early detection through routine blood tests allows healthcare providers to intervene before anemia becomes severe enough to cause serious complications, including heart problems. Your healthcare team will determine how often you need testing based on your stage of kidney disease and other health factors.^[8]

Classic Diagnostic Methods

Diagnosing nephrogenic anaemia requires several blood tests that work together to paint a complete picture of your condition. The most fundamental test is a complete blood count, commonly abbreviated as CBC. This test measures multiple components of your blood, but for anemia diagnosis, healthcare providers focus primarily on your hemoglobin level and your red blood cell count. Hemoglobin is the iron-rich protein inside red blood cells that carries oxygen from your lungs to the rest of your body. When you have anemia, your blood contains either too few red blood cells or not enough hemoglobin to meet your body’s oxygen needs.^[1]

Normal hemoglobin levels differ between men and women. For men, the normal range is typically 14 to 18 grams per deciliter (g/dL), while for women it is 12 to 16 g/dL. In people with chronic kidney disease, hemoglobin levels can drop significantly lower, sometimes falling as low as 4 grams per deciliter in severe cases. Healthcare providers typically consider treating anemia in dialysis patients when hemoglobin drops below 9 to 10 g/dL, though the exact threshold for starting treatment in patients not on dialysis may vary depending on symptoms.^[4][5]

Along with the complete blood count, doctors examine a peripheral blood smear, which involves looking at your blood cells under a microscope. In nephrogenic anaemia, this test typically shows normocytic, normochromic anemia, meaning the red blood cells appear normal in both size and color despite being fewer in number. This appearance helps distinguish nephrogenic anaemia from other types of anemia where the cells might be smaller, larger, or paler than normal. If the blood smear shows fragmented red blood cells alongside low platelet counts, this suggests a different condition called microangiopathic hemolytic anemia, which requires different investigation and treatment.^[5]

The reticulocyte count is another crucial diagnostic test. Reticulocytes are young red blood cells that have recently been released from the bone marrow. In a healthy person responding to anemia, the bone marrow increases production of red blood cells, so the reticulocyte count rises. However, in nephrogenic anaemia, the reticulocyte count remains low despite the anemia. This finding indicates that the bone marrow is not producing enough new red blood cells, confirming the diagnosis of a hypoproliferative anemia—one caused by inadequate production rather than excessive destruction or loss of red blood cells.^[5]

Iron studies form an essential part of the diagnostic workup because iron deficiency commonly accompanies kidney disease and can worsen anemia. These tests measure several different aspects of iron metabolism in your body. Serum iron measures the amount of iron circulating in your blood. Ferritin indicates how much iron your body has stored and is ready to use. Total iron-binding capacity (TIBC) reflects how much transferrin—the protein that transports iron in your blood—is available. Transferrin saturation (TSAT) shows what percentage of transferrin molecules are actually carrying iron at any given time.^[5]

For people with chronic kidney disease who are receiving dialysis and have hemoglobin below 10 g/dL, healthcare providers typically look for ferritin levels at or below 500 nanograms per milliliter (ng/mL) and transferrin saturation at or below 30 percent. For those not yet on dialysis, concerning levels include ferritin below 100 ng/mL with transferrin saturation below 40 percent, or ferritin below 300 ng/mL with transferrin saturation below 25 percent. These thresholds help determine whether adding intravenous iron therapy would benefit the patient.^[5]

Additional blood tests help rule out other causes of anemia that might be contributing to the problem. Vitamin B12 and folate levels are measured because deficiencies in these vitamins can cause anemia. Thyroid function tests are performed because thyroid disorders can also affect red blood cell production. In some cases, a bone marrow biopsy might be considered, though this is not routinely needed for diagnosis. When performed, it typically shows reduced numbers of red blood cell precursors in the bone marrow, confirming that production is impaired.^[5][10]

Tests to assess kidney function itself are essential for understanding the underlying cause of the anemia. Serum creatinine and blood urea nitrogen (BUN) tests measure waste products that healthy kidneys would normally filter out. Creatinine clearance or estimated glomerular filtration rate (eGFR) calculations provide a more precise measure of how well your kidneys are filtering blood. These kidney function tests help establish the stage of chronic kidney disease and correlate the degree of anemia with the severity of kidney damage.^[5]

Healthcare providers may also investigate potential sources of blood loss, as this can contribute to anemia in kidney disease patients. Blood in the stool, whether visible or detected only through testing, requires investigation to rule out gastrointestinal bleeding. Problems with the digestive system, including indigestion or changes in stool appearance such as blackening (which can indicate bleeding from the stomach), should be reported to your doctor. Infections can also temporarily worsen anemia, so identifying and treating infections such as recurrent urinary tract infections or infections around dialysis catheters is important.^[4]

The timing and frequency of these diagnostic tests vary depending on your stage of kidney disease and whether you are receiving treatment for anemia. People with earlier stages of chronic kidney disease typically need less frequent monitoring, while those on dialysis or receiving treatment with erythropoiesis-stimulating agents require regular monitoring to ensure hemoglobin levels remain in the target range and to detect any complications from treatment.^[5]

Diagnostics for Clinical Trial Qualification

When researchers conduct clinical trials to test new treatments for nephrogenic anaemia, they use specific diagnostic criteria to determine which patients can participate. These qualification criteria are more precise and standardized than those used in routine clinical care, ensuring that study participants have clearly defined disease characteristics and that results can be accurately compared across different patients and studies.

The primary qualification criterion for most clinical trials involving nephrogenic anaemia is the hemoglobin level. Trials typically specify a hemoglobin threshold below which patients are eligible to participate. For example, many studies of anemia in chronic kidney disease enroll patients with hemoglobin levels less than 10 g/dL, though some trials may use slightly different cutoffs such as less than 9 g/dL or less than 11 g/dL depending on the study design and the treatment being tested. This hemoglobin requirement ensures that enrolled patients actually have anemia that is significant enough to potentially benefit from the intervention being studied.^[5]

Clinical trials also require documentation of chronic kidney disease stage using standardized measures of kidney function. Most trials specify a minimum duration of kidney disease to distinguish chronic kidney disease from acute kidney injury. The stage of kidney disease, determined by estimated glomerular filtration rate (eGFR) or creatinine clearance measurements, often forms part of the eligibility criteria. Some trials focus specifically on patients receiving dialysis, while others enroll only those with chronic kidney disease who are not yet on dialysis. This distinction is important because the characteristics and treatment of anemia can differ between these patient populations.^[5]

Iron status measurements serve as another key qualification criterion in many trials. Studies testing new anemia treatments often require participants to have adequate iron stores before enrollment, typically defined by ferritin levels above a certain threshold (such as greater than 100 ng/mL) and transferrin saturation above a minimum percentage (such as greater than 20 percent). This requirement ensures that any lack of response to treatment is not simply due to iron deficiency, which would confound the study results. Some trials may provide iron supplementation to all participants to standardize iron status before testing the primary intervention.^[5]

Clinical trials typically exclude patients whose anemia might have causes other than kidney disease. To accomplish this, researchers require additional blood tests at screening. Normal vitamin B12 and folate levels must be documented to rule out vitamin deficiency anemia. Normal or adequately treated thyroid function may be required. Tests for inflammatory markers or other blood disorders might be performed to exclude conditions that could independently cause or contribute to anemia. This thorough screening process ensures that study results specifically reflect the treatment’s effect on kidney disease-related anemia rather than on anemia from mixed causes.^[10]

Many trials require participants to be either treatment-naive (not currently receiving anemia treatment) or to undergo a washout period during which existing treatments are stopped before the trial begins. For patients receiving erythropoiesis-stimulating agents, this washout period allows hemoglobin levels to drop to a level that will permit assessment of the new treatment’s effectiveness. The duration of washout varies but is typically several weeks to months, depending on the half-life of the medication being discontinued.^[5]

Throughout clinical trials, frequent monitoring with the same diagnostic tests used for qualification helps researchers track response to treatment. Hemoglobin levels are measured at regular intervals, often as frequently as weekly or biweekly during the initial treatment phase and monthly during maintenance phases. Iron studies are repeated periodically to ensure iron stores remain adequate. Kidney function tests are performed regularly to monitor disease progression and ensure that changes in anemia are not simply due to worsening or improving kidney function. Complete blood counts with differential and reticulocyte counts help characterize the type of response to treatment and detect any unexpected changes in other blood cell lines.^[5]

Safety monitoring in clinical trials for nephrogenic anaemia includes specific blood pressure measurements, since some anemia treatments can increase blood pressure. Participants may undergo regular blood pressure checks, and those with uncontrolled hypertension might be excluded from certain trials. Blood tests to detect potential complications include monitoring for signs of blood clots or changes in blood chemistry. Some trials require periodic imaging or other specialized tests to monitor for cardiovascular complications, which are a concern when raising hemoglobin levels too quickly or too high.^[5]

Newer clinical trials investigating novel treatments for nephrogenic anaemia may include additional specialized diagnostic tests. For example, studies of medications that affect iron metabolism might measure levels of hepcidin, a hormone that regulates iron absorption and distribution in the body. Trials testing drugs that stimulate red blood cell production through pathways different from traditional erythropoietin might measure levels of various growth factors or genetic markers of red blood cell production. These advanced tests help researchers understand how new treatments work and identify patients most likely to respond.^[6]

The diagnostic criteria for clinical trial enrollment are designed to balance scientific rigor with patient safety. Strict inclusion and exclusion criteria help ensure that study results are clear and interpretable, but they also mean that many patients with nephrogenic anaemia may not qualify for specific trials. If you are interested in participating in a clinical trial for anemia of chronic kidney disease, your healthcare provider can help determine whether you meet the qualification criteria for available studies and discuss whether trial participation would be appropriate for your individual situation.